Immune privilege of corneal allografts

Ocul Immunol Inflamm. 2010 Jun;18(3):162-71. doi: 10.3109/09273948.2010.486100.


Corneal transplantation has been performed successfully for over 100 years. Normally, HLA typing and systemic immunosuppressive drugs are not utilized, yet 90% of corneal allografts survive. In rodents, corneal allografts representing maximal histoincompatibility enjoy >50% survival even without immunosuppressive drugs. By contrast, other categories of transplants are invariably rejected in such donor/host combinations. The acceptance of corneal allografts compared to other categories of allografts is called immune privilege. The cornea expresses factors that contribute to immune privilege by preventing the induction and expression of immune responses to histocompatibility antigens on the corneal allograft. Among these are soluble and cell membrane molecules that block immune effector elements and also apoptosis of T lymphocytes. However, some conditions rob the corneal allograft of its immune privilege and promote rejection, which remains the leading cause of corneal allograft failure. Recent studies have examined new strategies for restoring immune privilege to such high-risk hosts.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Cornea / immunology*
  • Corneal Diseases / surgery
  • Corneal Transplantation*
  • Graft Rejection / immunology
  • Graft Survival / immunology*
  • Humans
  • Immunity, Cellular*
  • T-Lymphocytes / immunology*
  • Transplantation, Homologous / immunology